COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry
A non-probability sampling method will be used. Subjects will be requested to enroll in the
registry after having completed or discontinued participation in a Phase 2 or 3 study
Observational Model: Cohort, Time Perspective: Prospective
Incidence of malignancies, AIDS-defining events, other clinical events of importance, and death.
Information regarding clinical outcome will be collected every 6 months. Deaths will be collected on an ongoing basis.
United States: Food and Drug Administration